Castle Biosciences’ DecisionDx-Melanoma test consistently stratifies patients into risk groups with significantly different outcomes, according to a new independent meta-analysis in Cancers.
For the study, the authors evaluated peer-reviewed articles that analyzed DecisionDx-Melanoma risk class data alongside at least one survival-based metric with a minimum of three years of follow-up. Systematic reviews, meta-analyses, and studies without at least three years of patient follow-up were excluded. Following these criteria and additional analyses using Oxford Center guidelines and the Quality in Prognosis Studies (QUIPS) tool, which assesses six domains of bias, a total of 13 studies were included in the meta-analysis.
Across all studies, the DecisionDx-Melanoma test consistently stratified patients into risk groups with significantly different outcomes.
The five-year melanoma-specific survival rates were:
- 8% for patients with a Class 1A/lowest risk test result,
- 6% for patients with a Class 1B/2A/increased risk test result and
- 4% for patients with a Class 2B/highest risk test result.
Similar trends were observed for recurrence-free and distant metastasis-free survival, showing a significant separation of risk between patients with Class 1A and Class 2B test results.
“The ability to more accurately stratify patients based on their risk of recurrence and metastasis has the potential to significantly improve personalized care strategies, optimizing the balance between treatment efficacy and quality of life for patients with [cutaneous melanoma],” the study authors conclude.
“We believe the clinical performance of our DecisionDx-Melanoma test is unmatched by other tests currently on the market, both in its ability to provide precise and clinically meaningful risk stratification as well as accurate predictions of sentinel lymph node positivity,” said Matthew Goldberg, MD, board-certified dermatologist and dermatopathologist, and Senior Vice President, medical, of Castle Biosciences. “This independent publication adds to the robust body of evidence supporting DecisionDx-Melanoma and provides a compelling analysis highlighting the broad utility of the test to improve care for patients with melanoma.”
